Stocks and Investing Stocks and Investing
Wed, March 16, 2022
Tue, March 15, 2022

Gregory Renza Maintained (SPRB) at Buy with Decreased Target to $9 on, Mar 15th, 2022


Published on 2024-10-27 20:05:38 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Maintained "Spruce Biosciences, Inc." (SPRB) at Buy with Decreased Target from $13 to $9 on, Mar 15th, 2022.

Gregory has made no other calls on SPRB in the last 4 months.



There are 6 other peers that have a rating on SPRB. Out of the 6 peers that are also analyzing SPRB, 2 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Ritu Baral of "Cowen & Co." Downgraded from Buy to Hold on, Tuesday, November 23rd, 2021
  • Joseph Schwartz of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $5 on, Tuesday, November 16th, 2021


These are the ratings of the 4 analyists that currently disagree with Gregory


  • Aydin Huseynov of "Ladenburg Thalmann" Initiated at Strong Buy and Held Target at $6 on, Tuesday, March 8th, 2022
  • Hartaj Singh of "Oppenheimer" Initiated at Buy and Held Target at $15 on, Friday, December 17th, 2021
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $6 on, Tuesday, November 16th, 2021
  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, November 16th, 2021
Contributing Sources